Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Strathspey Crown Announces Issuance of US Patent for Digital Root Combinatorial Titration of Gene (DNA) Modulation Technologies

Strathspey Crown LLC
Posted on: 11 Dec 18
Strathspey Crown Announces Issuance of US Patent for Digital Root Combinatorial Titration of Gene (DNA) Modulation Technologies

PR Newswire

NEWPORT BEACH, Calif., Dec. 11, 2018

NEWPORT BEACH, Calif., Dec. 11, 2018 /PRNewswire/ -- Strathspey Crown LLC (SC), a growth equity firm specializing in healthcare and lifestyle technology, today announced that the United States Patent and Trademark Office has issued US Patent 10,076,672 (Inventor: Robert Edward Grant) covering the use of numerical digital roots to generate computer-input data that establishes an appropriate radiation parameter for influencing cellular structure. This patent coincides with an additional US Patent granted to Strathspey Crown LLC for the system and method of implementing this digital root technology using sound and light frequencies.  

The primary claim of US Patent 10,076,672 is a method for employing digital root combinatorial analysis to define an irradiation protocol for the modulation of cellular expression. Using data from the physical characteristics of the cell itself, the computer calculates targeted formulae in order to further refine the radiation target into a specific range of oscillation resonance. The digital root creates an operational range for the radiation unit that can establish a targeted range of irradiation rather than broad spectrums used in irradiation techniques that remain the current standard of care. During the radiation treatment, the data is monitored and adjusted inducing the desired genotypic or phenotypic expression.

Robert Edward Grant, Founder and Chairman of Strathspey Crown LLC, commented, "This patent, along with our rapidly expanding intellectual property portfolio particularly in the field of Gene Modulation, has the potential to change the paradigm of care for patients.  This patent represents a significant step forward in revolutionizing the way we are able to treat patients in a less invasive manner. When radiation is applied to specific cells rather than a general spectrum of tissue, we believe that patients will be able to get back to their lives sooner. We are thrilled to continue the development of technologies in this exciting and fast-growing field."

Strathspey Crown presently holds several patents and new applications in pending status with the US Patent and Trademark office, each addressing significant high-growth market segments across medicine and genetic modulation, as well as, miniature implantable smart-ocular technologies among several fields of emerging technology.

About Strathspey Crown LLC: Strathspey Crown is a growth equity firm whose subsidiaries specialize in fields across lifestyle healthcare, clean energy, and financial technology. For more information, please visit www.strathspeycrown.com.

Strathspey Crown LLC Press Contact
Tel: +1-949-260-1700

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/strathspey-crown-announces-issuance-of-us-patent-for-digital-root-combinatorial-titration-of-gene-dna-modulation-technologies-300763121.html

SOURCE Strathspey Crown LLC

PR Newswire
www.prnewswire.com

Last updated on: 11/12/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.